{
    "document_id": "D-2023-1750",
    "LinkTitle": "D-2023-1750",
    "file_name": "D-2023-1750.pdf",
    "file_path": "/Users/JADEPOTTER5/Downloads/DMP-MT/processed_data/pdfs_new/org_pdfs/D-2023-1750.pdf",
    "metadata": {
        "title": "STRADACEF",
        "author": "N/A",
        "num_pages": 6
    },
    "content": {
        "full_text": "STRADACEF\nA Data Management Plan created using DMPonline.be\nCreators: \nDorian Vanneste, Isabel Spriet\nAffiliation: \nKU Leuven (KUL)\nFunder: \nFonds voor Wetenschappelijk Onderzoek - Research Foundation Flanders (FWO)\nTemplate: \nFWO DMP (Flemish Standard DMP)\nPrincipal Investigator:\n \nIsabel Spriet\nData Manager:\n \nIsabel Spriet\nProject Administrator:\n \nIsabel Spriet\nGrant number / URL: \nt003922n\nID: \n197522\nStart date: \n01-08-2023\nEnd date: \n01-08-2023\nProject abstract:\nThe general objective of the STRADA-CEF trial is to perform a randomised controlled trial (RCT) investigating the clinical benefit of\nstratified every 24-hour (q24h) vs. q12h 2g ceftriaxone therapy in patients with severe community-acquired pneumonia (sCAP) based on\nthe predicted probability of augmented renal clearance on the next day (P\nARC\n).\nPatients: patients admitted to the intensive care unit (ICU) and treated with ceftriaxone for sCAP.\nIntervention: dose stratification for ceftriaxone from 2g q24h to 2g q12h based on daily assessment of P\nARC\n.\nComparison: patients receiving the standard-of-care 2g q24h ceftriaxone dose regimen, regardless of P\nARC\n.\nOutcome: reduction of the ICU length of stay.\nIn a population PK and exposure-response (i.e., efficacy and safety) analysis and pharmaco-economic analysis , the dose-exposure-\n(biomarker-)response-cost relationship of ceftriaxone will be investigated, providing more insight into the study results. Finally, all results\nwill be disseminated to the relevant stakeholders to facilitate and promote implementation of this simple dose stratification strategy in\ndaily clinical practice.\n \n \n \n \n \n \nLast modified: \n17-03-2023\nCreated using DMPonline.be. Last modiﬁed 17 March 2023\n1 of 6\nSTRADACEF\nFWO DMP (Flemish Standard DMP)\n1. Research Data Summary\nList and describe all datasets or research materials that you plan to generate/collect or reuse during your research\nproject. For each dataset or data type (observational, experimental etc.), provide a short name & description (sufficient\nfor yourself to know what data it is about), indicate whether the data are newly generated/collected or reused, digital or\nphysical, also indicate the type of the data (the kind of content), its technical format (file extension), and an estimate of\nthe upper limit of the volume of the data.\n \n \n \n \nOnly for digital data\nOnly for\ndigital data \nOnly for\ndigital data \nOnly for\nphysical\ndata\nDataset Name\nDescription\nNew or\nreused\nDigital or\nPhysical\nDigital Data Type\nDigital Data\nformat\nDigital data\nvolume\n(MB/GB/TB)\nPhysical\nvolume\n \n \nPlease\nchoose from\nthe following\noptions:\nGenerate\nnew data\nReuse\nexisting\ndata\nPlease\nchoose from\nthe following\noptions:\nDigital\nPhysical\nPlease choose from the\nfollowing options:\nObservational\nExperimental\nCompiled/aggregated\ndata\nSimulation data\nSoftware\nOther\nNA\nPlease\nchoose from\nthe following\noptions:\n.por,\n.xml,\n.tab,\n.cvs,.pdf,\n.txt, .rtf,\n.dwg,\n.gml, …\nNA\nPlease\nchoose from\nthe following\noptions:\n<100MB\n<1GB\n<100GB\n<1TB\n<5TB\n<10TB\n<50TB\n>50TB\nNA\n \nSTRADACEF_REDCAP\nExperimental\nand\nquantative\ndata of the\nparticipants\nNew\nDigital\nObservational and\nexperimental\n.xml\n<100GB\n \nSTRADACEF_Bio\nBiological\nmaterial from\nthe patients\nNew\nPhysical\n \n \n \n1500\nsamples\nSTRADACEF_stat\nStatistical\ndata\nNew\nDigital\nOther\n.csv\n<1GB\n \nSTRADACEF_mod\nStatistical\nmodels\ncreated from\ndata\nNew\nDigital\nSimulation\n.mod\n<1GB\n \n  \nIf you reuse existing data, please specify the source, preferably by using a persistent identifier (e.g. DOI, Handle, URL\netc.) per dataset or data type:\nNot applicable\n  \nAre there any ethical issues concerning the creation and/or use of the data (e.g. experiments on humans or animals,\ndual use)? Describe these issues in the comment section. Please refer to specific datasets or data types when\nappropriate.\nYes, human subject data\nCreated using DMPonline.be. Last modiﬁed 17 March 2023\n2 of 6\nThe STRADACEF_REDCAP dataset contains personal data from the patients such as age, sex, medical history, biochemical\ndata. This data is considered sensitive and must therefore be handled accordingly as to not raise ethical concerns. All data will be\npseudonymised at the level of participating centres.\nInformed consent will be asked from the patients, guardian, or relatives upon inclusion in the trial.\n  \nWill you process personal data? If so, briefly describe the kind of personal data you will use in the comment section.\nPlease refer to specific datasets or data types when appropriate.\nYes\nThe STRADACEF_REDCAP dataset will contain personal data, such as age, sex, medical history, and biochemical data, which\nwill be used for descriptive statistics as well as for the creation of a predictive model.\n \nData will not contain person-identifiable information and will be pseudonymised.\n  \nDoes your work have potential for commercial valorization (e.g. tech transfer, for example spin-offs, commercial\nexploitation, …)? If so, please comment per dataset or data type where appropriate.\nNo\n \n  \nDo existing 3rd party agreements restrict exploitation or dissemination of the data you (re)use (e.g. Material/Data\ntransfer agreements/ research collaboration agreements)? If so, please explain in the comment section to what data they\nrelate and what restrictions are in place.\nNo\n \n  \nAre there any other legal issues, such as intellectual property rights and ownership, to be managed related to the data\nyou (re)use? If so, please explain in the comment section to what data they relate and which restrictions will be\nasserted.\nNo\n \n  \n2. Documentation and Metadata\nClearly describe what approach will be followed to capture the accompanying information necessary to keep data\nunderstandable and usable, for yourself and others, now and in the future (e.g., in terms of documentation levels and\ntypes required, procedures used, Electronic Lab Notebooks, README.txt files, Codebook.tsv etc. where this information\nis recorded).\nData will be collected in a common electronic CRF, each participating centre will have access to the eCRF files of their patients.\nOnly the coordinating investigators will have access to all patient eCRF files.\nSamples will be collected by local staff at participating centres, and shipped every 6 months to the coordinating centre. Samples\nwill be linked to patient data (from STRADACEF_REDCAP) using QR-coded sample vials.\nStatistical and model data will be created within specific software, e.g. R, NONNEM. The statistical code will contain in-file\ndocumentation to clarify the statistical analysis.\nCreated using DMPonline.be. Last modiﬁed 17 March 2023\n3 of 6\nFor all datasets, README.txt files will be made to make the information in each dataset explicit and understandable to third\nparties.\n  \nWill a metadata standard be used to make it easier to find and reuse the data? If so, please specify (where appropriate\nper dataset or data type) which metadata standard will be used. If not, please specify (where appropriate per dataset or\ndata type) which metadata will be created to make the data easier to find and reuse.\nNo\nWe will export a metadata survey from REDCAP providing an overview of all contained data within REDCAP.\nAll sampling moments will also be collected in REDCAP and therefore also be available from the metadata survey.\n  \n3. Data storage & back-up during the research project\nWhere will the data be stored?\nDuring the project all patient information will be stored in REDCAP, which is stored on a UZ Leuven server. The REDCAP\ndatabase will be locked after completion of the study.\nAfter the study all processed data will be stored in a password protected folder on a server at UZ Leuven and KU Leuven.\nBiological data will be stored in the UZ Leuven Biobank.\n  \nHow will the data be backed up?\nThe UZ/KU Leuven servers provide automatic back-ups.\nWe will regularly, i.e. monthly, back-up the data from REDCAP by using the integrated back-up function.\nSamples will be divided in three aliquots.\n  \nIs there currently sufficient storage & backup capacity during the project? If yes, specify concisely.\nIf no or insufficient storage or backup capacities are available, then explain how this will be taken care of.\nYes\nThe UZ/KU Leuven server provides amply enough storage space and back-up capacity for all our data. We anticipate a data\nvolume of no more than 10 GB which amply fits the storage space.\n \n  \nHow will you ensure that the data are securely stored and not accessed or modified by unauthorized persons?\nThe data folders will be password protected. The biobank is only accessible for members of the research team with an\nauthorisation.\nOnly members of the research team will have access to these folders and to the biobank.\n  \nWhat are the expected costs for data storage and backup during the research project? How will these costs be covered?\nThe cost for REDCAP (€ 80/year) has been included in the FWO/TBM funding application.\nREDCAP is provided by UZ/KU Leuven, and the costs (approximately € 29.000) for support by the clinical trial centre of UZ\nLeuven for eCRF design and validation, and access and data management are covered by the FWO/TBM funding.\n \n  \nCreated using DMPonline.be. Last modiﬁed 17 March 2023\n4 of 6\n4. Data preservation after the end of the research project\nWhich data will be retained for at least five years (or longer, in agreement with other retention policies that are\napplicable) after the end of the project? In case some data cannot be preserved, clearly state the reasons for this (e.g.\nlegal or contractual restrictions, storage/budget issues, institutional policies...).\nIn accordance with the KU Leuven research data management data policy, all data will be retained for a period of minimum 10\nyears after the end of the project in a safe, secure, and sustainable way for the purposes of reproducibility, verification, and\npotential reuse. All this will be done in accordance with the General Data Protection Regulation.\n  \nWhere will these data be archived (stored and curated for the long-term)?\nAfter the study all processed data will be stored in a password protected folder on a server at UZ Leuven and KU Leuven.\nBiological data will be stored in the UZ Leuven Biobank.\n  \nWhat are the expected costs for data preservation during the expected retention period? How will these costs be\ncovered?\nStorage on the UZ/KU Leuven folder is provided by the organisation.\nStorage in the UZ Leuven Biobank will approximately cost € 1000/year.\n  \n5. Data sharing and reuse\nWill the data (or part of the data) be made available for reuse after/during the project?  In the comment section please\nexplain per dataset or data type which data will be made available.\nYes, in a restricted access repository (after approval, institutional access only, …)\nData will be stored on our internal servers and will be made available to (internal or external) third parties upon reasonable\nrequest and after ethical approval.\nBiological samples for which after the completion of the study aliquots are left, can be made available to (internal or external) third\nparties upon reasonable request and after ethical approval.\n  \nIf access is restricted, please specify who will be able to access the data and under what conditions.\nResearch team members will have access to the data and will provide a copy to authorized third parties after ethical approval and\ndata transfer agreement.\n  \nAre there any factors that restrict or prevent the sharing of (some of) the data (e.g. as defined in an agreement with a 3rd\nparty, legal restrictions)? Please explain in the comment section per dataset or data type where appropriate.\nYes, Ethical aspects\nFor ethical concerns, as mentioned in part 1, patient data contains no person-identifiable information and will be pseudonymised.\nData or biological samples will only be shared after ethical approval.\n  \nWhere will the data be made available? If already known, please provide a repository per dataset or data type.\nCreated using DMPonline.be. Last modiﬁed 17 March 2023\n5 of 6\nData will not be made publicly available.\n  \nWhen will the data be made available?\nN/A\n  \nWhich data usage licenses are you going to provide? If none, please explain why.\nUpon sharing data with third parties, a data transfer agreement will be drafted and signed by all involved parties.\n  \nDo you intend to add a PID/DOI/accession number to your dataset(s)? If already available, you have the option to provide\nit in the comment section.\nNo\n \n  \nWhat are the expected costs for data sharing? How will these costs be covered?\nN/A\n  \n6. Responsibilities\nWho will manage data documentation and metadata during the research project?\nIsabel Spriet, Matthias Gijsen, and Dorian Vanneste \nWho will manage data storage and backup during the research project?\nIsabel Spriet, Matthias Gijsen, and Dorian Vanneste \nWho will manage data preservation and sharing?\nIsabel Spriet \nWho will update and implement this DMP?\nIsabel Spriet, Matthias Gijsen and Dorian Vanneste \nCreated using DMPonline.be. Last modiﬁed 17 March 2023\n6 of 6"
    },
    "clean_full_text": "STRADACEF A Data Management Plan created using DMPonline.be Creators: Dorian Vanneste, Isabel Spriet Affiliation: KU Leuven (KUL) Funder: Fonds voor Wetenschappelijk Onderzoek - Research Foundation Flanders (FWO) Template: FWO DMP (Flemish Standard DMP) Principal Investigator: Isabel Spriet Data Manager: Isabel Spriet Project Administrator: Isabel Spriet Grant number / URL: t003922n ID: 197522 Start date: 01-08-2023 End date: 01-08-2023 Project abstract: The general objective of the STRADA-CEF trial is to perform a randomised controlled trial (RCT) investigating the clinical benefit of stratified every 24-hour (q24h) vs. q12h 2g ceftriaxone therapy in patients with severe community-acquired pneumonia (sCAP) based on the predicted probability of augmented renal clearance on the next day (P ARC ). Patients: patients admitted to the intensive care unit (ICU) and treated with ceftriaxone for sCAP. Intervention: dose stratification for ceftriaxone from 2g q24h to 2g q12h based on daily assessment of P ARC . Comparison: patients receiving the standard-of-care 2g q24h ceftriaxone dose regimen, regardless of P ARC . Outcome: reduction of the ICU length of stay. In a population PK and exposure-response (i.e., efficacy and safety) analysis and pharmaco-economic analysis , the dose-exposure- (biomarker-)response-cost relationship of ceftriaxone will be investigated, providing more insight into the study results. Finally, all results will be disseminated to the relevant stakeholders to facilitate and promote implementation of this simple dose stratification strategy in daily clinical practice. Last modified: 17-03-2023 Created using DMPonline.be. Last modiﬁed 17 March 2023 1 of 6 STRADACEF FWO DMP (Flemish Standard DMP) 1. Research Data Summary List and describe all datasets or research materials that you plan to generate/collect or reuse during your research project. For each dataset or data type (observational, experimental etc.), provide a short name & description (sufficient for yourself to know what data it is about), indicate whether the data are newly generated/collected or reused, digital or physical, also indicate the type of the data (the kind of content), its technical format (file extension), and an estimate of the upper limit of the volume of the data. Only for digital data Only for digital data Only for digital data Only for physical data Dataset Name Description New or reused Digital or Physical Digital Data Type Digital Data format Digital data volume (MB/GB/TB) Physical volume Please choose from the following options: Generate new data Reuse existing data Please choose from the following options: Digital Physical Please choose from the following options: Observational Experimental Compiled/aggregated data Simulation data Software Other NA Please choose from the following options: .por, .xml, .tab, .cvs,.pdf, .txt, .rtf, .dwg, .gml, … NA Please choose from the following options: <100MB <1GB <100GB <1TB <5TB <10TB <50TB >50TB NA STRADACEF_REDCAP Experimental and quantative data of the participants New Digital Observational and experimental .xml <100GB STRADACEF_Bio Biological material from the patients New Physical 1500 samples STRADACEF_stat Statistical data New Digital Other .csv <1GB STRADACEF_mod Statistical models created from data New Digital Simulation .mod <1GB If you reuse existing data, please specify the source, preferably by using a persistent identifier (e.g. DOI, Handle, URL etc.) per dataset or data type: Not applicable Are there any ethical issues concerning the creation and/or use of the data (e.g. experiments on humans or animals, dual use)? Describe these issues in the comment section. Please refer to specific datasets or data types when appropriate. Yes, human subject data Created using DMPonline.be. Last modiﬁed 17 March 2023 2 of 6 The STRADACEF_REDCAP dataset contains personal data from the patients such as age, sex, medical history, biochemical data. This data is considered sensitive and must therefore be handled accordingly as to not raise ethical concerns. All data will be pseudonymised at the level of participating centres. Informed consent will be asked from the patients, guardian, or relatives upon inclusion in the trial. Will you process personal data? If so, briefly describe the kind of personal data you will use in the comment section. Please refer to specific datasets or data types when appropriate. Yes The STRADACEF_REDCAP dataset will contain personal data, such as age, sex, medical history, and biochemical data, which will be used for descriptive statistics as well as for the creation of a predictive model. Data will not contain person-identifiable information and will be pseudonymised. Does your work have potential for commercial valorization (e.g. tech transfer, for example spin-offs, commercial exploitation, …)? If so, please comment per dataset or data type where appropriate. No Do existing 3rd party agreements restrict exploitation or dissemination of the data you (re)use (e.g. Material/Data transfer agreements/ research collaboration agreements)? If so, please explain in the comment section to what data they relate and what restrictions are in place. No Are there any other legal issues, such as intellectual property rights and ownership, to be managed related to the data you (re)use? If so, please explain in the comment section to what data they relate and which restrictions will be asserted. No 2. Documentation and Metadata Clearly describe what approach will be followed to capture the accompanying information necessary to keep data understandable and usable, for yourself and others, now and in the future (e.g., in terms of documentation levels and types required, procedures used, Electronic Lab Notebooks, README.txt files, Codebook.tsv etc. where this information is recorded). Data will be collected in a common electronic CRF, each participating centre will have access to the eCRF files of their patients. Only the coordinating investigators will have access to all patient eCRF files. Samples will be collected by local staff at participating centres, and shipped every 6 months to the coordinating centre. Samples will be linked to patient data (from STRADACEF_REDCAP) using QR-coded sample vials. Statistical and model data will be created within specific software, e.g. R, NONNEM. The statistical code will contain in-file documentation to clarify the statistical analysis. Created using DMPonline.be. Last modiﬁed 17 March 2023 3 of 6 For all datasets, README.txt files will be made to make the information in each dataset explicit and understandable to third parties. Will a metadata standard be used to make it easier to find and reuse the data? If so, please specify (where appropriate per dataset or data type) which metadata standard will be used. If not, please specify (where appropriate per dataset or data type) which metadata will be created to make the data easier to find and reuse. No We will export a metadata survey from REDCAP providing an overview of all contained data within REDCAP. All sampling moments will also be collected in REDCAP and therefore also be available from the metadata survey. 3. Data storage & back-up during the research project Where will the data be stored? During the project all patient information will be stored in REDCAP, which is stored on a UZ Leuven server. The REDCAP database will be locked after completion of the study. After the study all processed data will be stored in a password protected folder on a server at UZ Leuven and KU Leuven. Biological data will be stored in the UZ Leuven Biobank. How will the data be backed up? The UZ/KU Leuven servers provide automatic back-ups. We will regularly, i.e. monthly, back-up the data from REDCAP by using the integrated back-up function. Samples will be divided in three aliquots. Is there currently sufficient storage & backup capacity during the project? If yes, specify concisely. If no or insufficient storage or backup capacities are available, then explain how this will be taken care of. Yes The UZ/KU Leuven server provides amply enough storage space and back-up capacity for all our data. We anticipate a data volume of no more than 10 GB which amply fits the storage space. How will you ensure that the data are securely stored and not accessed or modified by unauthorized persons? The data folders will be password protected. The biobank is only accessible for members of the research team with an authorisation. Only members of the research team will have access to these folders and to the biobank. What are the expected costs for data storage and backup during the research project? How will these costs be covered? The cost for REDCAP (€ 80/year) has been included in the FWO/TBM funding application. REDCAP is provided by UZ/KU Leuven, and the costs (approximately € 29.000) for support by the clinical trial centre of UZ Leuven for eCRF design and validation, and access and data management are covered by the FWO/TBM funding. Created using DMPonline.be. Last modiﬁed 17 March 2023 4 of 6 4. Data preservation after the end of the research project Which data will be retained for at least five years (or longer, in agreement with other retention policies that are applicable) after the end of the project? In case some data cannot be preserved, clearly state the reasons for this (e.g. legal or contractual restrictions, storage/budget issues, institutional policies...). In accordance with the KU Leuven research data management data policy, all data will be retained for a period of minimum 10 years after the end of the project in a safe, secure, and sustainable way for the purposes of reproducibility, verification, and potential reuse. All this will be done in accordance with the General Data Protection Regulation. Where will these data be archived (stored and curated for the long-term)? After the study all processed data will be stored in a password protected folder on a server at UZ Leuven and KU Leuven. Biological data will be stored in the UZ Leuven Biobank. What are the expected costs for data preservation during the expected retention period? How will these costs be covered? Storage on the UZ/KU Leuven folder is provided by the organisation. Storage in the UZ Leuven Biobank will approximately cost € 1000/year. 5. Data sharing and reuse Will the data (or part of the data) be made available for reuse after/during the project? In the comment section please explain per dataset or data type which data will be made available. Yes, in a restricted access repository (after approval, institutional access only, …) Data will be stored on our internal servers and will be made available to (internal or external) third parties upon reasonable request and after ethical approval. Biological samples for which after the completion of the study aliquots are left, can be made available to (internal or external) third parties upon reasonable request and after ethical approval. If access is restricted, please specify who will be able to access the data and under what conditions. Research team members will have access to the data and will provide a copy to authorized third parties after ethical approval and data transfer agreement. Are there any factors that restrict or prevent the sharing of (some of) the data (e.g. as defined in an agreement with a 3rd party, legal restrictions)? Please explain in the comment section per dataset or data type where appropriate. Yes, Ethical aspects For ethical concerns, as mentioned in part 1, patient data contains no person-identifiable information and will be pseudonymised. Data or biological samples will only be shared after ethical approval. Where will the data be made available? If already known, please provide a repository per dataset or data type. Created using DMPonline.be. Last modiﬁed 17 March 2023 5 of 6 Data will not be made publicly available. When will the data be made available? N/A Which data usage licenses are you going to provide? If none, please explain why. Upon sharing data with third parties, a data transfer agreement will be drafted and signed by all involved parties. Do you intend to add a PID/DOI/accession number to your dataset(s)? If already available, you have the option to provide it in the comment section. No What are the expected costs for data sharing? How will these costs be covered? N/A 6. Responsibilities Who will manage data documentation and metadata during the research project? Isabel Spriet, Matthias Gijsen, and Dorian Vanneste Who will manage data storage and backup during the research project? Isabel Spriet, Matthias Gijsen, and Dorian Vanneste Who will manage data preservation and sharing? Isabel Spriet Who will update and implement this DMP? Isabel Spriet, Matthias Gijsen and Dorian Vanneste Created using DMPonline.be. Last modiﬁed 17 March 2023 6 of 6"
}